BR112022000507A2 - Formulações de (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida - Google Patents

Formulações de (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida

Info

Publication number
BR112022000507A2
BR112022000507A2 BR112022000507A BR112022000507A BR112022000507A2 BR 112022000507 A2 BR112022000507 A2 BR 112022000507A2 BR 112022000507 A BR112022000507 A BR 112022000507A BR 112022000507 A BR112022000507 A BR 112022000507A BR 112022000507 A2 BR112022000507 A2 BR 112022000507A2
Authority
BR
Brazil
Prior art keywords
picolinamide
methylpropyl
trifluoro
trifluoromethyl
methoxy
Prior art date
Application number
BR112022000507A
Other languages
English (en)
Inventor
Hubert Thoma
Paulo Santos
Rohit Lowalekar
Vivek Dubey
Xianbin Tian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112022000507A2 publication Critical patent/BR112022000507A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

formulações de (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida. a presente invenção refere-se a uma composição farmacêutica que compreende a. (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida ou um sal farmaceuticamente aceitável, polimorfo ou cocristal da mesma, b. amidoglicolato de sódio e c. estearilfumarato de sódio. uma composição farmacêutica que compreende a. (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida ou um sal farmaceuticamente aceitável, polimorfo ou cocristal da mesma, b. crospovidona e c. este-arilfumarato de sódio. as referidas composições para uso no tratamento de bronquiectasia, distúrbio pulmonar obstrutivo crônico, fibrose cística, bronquite crônica ou asma. processo para a fabricação das referidas composições, que compreende as etapas de: (a) mistura de (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida em conjunto com amidoglicolato de sódio para formar um material, (b) moagem úmida do material para formar uma pluralidade de grânulos, (c) mistura dos grânulos com estearilfumarato de sódio e amidoglicolato de sódio para formar uma mistura final, e (d) compressão da mistura final em um comprimido.
BR112022000507A 2019-07-15 2020-07-15 Formulações de (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida BR112022000507A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201911028435 2019-07-15
IN202011023329 2020-06-03
PCT/IB2020/056661 WO2021009695A1 (en) 2019-07-15 2020-07-15 Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide

Publications (1)

Publication Number Publication Date
BR112022000507A2 true BR112022000507A2 (pt) 2022-05-10

Family

ID=71738249

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000507A BR112022000507A2 (pt) 2019-07-15 2020-07-15 Formulações de (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida

Country Status (13)

Country Link
US (1) US11865109B2 (pt)
EP (1) EP3999063A1 (pt)
JP (1) JP2022541178A (pt)
KR (1) KR20220035421A (pt)
CN (1) CN114007616A (pt)
AU (1) AU2020313422A1 (pt)
BR (1) BR112022000507A2 (pt)
CA (1) CA3143431A1 (pt)
CL (1) CL2022000079A1 (pt)
IL (1) IL288577A (pt)
MX (1) MX2022000549A (pt)
TW (1) TW202116312A (pt)
WO (1) WO2021009695A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109939A1 (zh) * 2021-12-17 2023-06-22 苏州晶云药物科技股份有限公司 吡啶类衍生物的晶型及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8247436B2 (en) * 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2582362A1 (en) 2010-06-21 2013-04-24 Zaklady Farmaceutyczne "Polpharma" S.A. Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof
ES2952878T3 (es) * 2016-08-08 2023-11-06 Hetero Labs Ltd Una composición antirretroviral multiclase
AU2017362350B2 (en) 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators
BR112019012335A2 (pt) 2016-12-16 2020-03-03 Cystic Fibrosis Foundation Therapeutics, Inc. Derivados de heteroarila bicíclica como potenciadores de cftr
ES2891527T3 (es) 2016-12-19 2022-01-28 Novartis Ag Nuevos derivados de ácido picolínico y su uso como intermedios

Also Published As

Publication number Publication date
CN114007616A (zh) 2022-02-01
KR20220035421A (ko) 2022-03-22
EP3999063A1 (en) 2022-05-25
CA3143431A1 (en) 2021-01-21
MX2022000549A (es) 2022-02-10
AU2020313422A1 (en) 2022-01-27
IL288577A (en) 2022-02-01
CL2022000079A1 (es) 2022-11-11
US20210015804A1 (en) 2021-01-21
US11865109B2 (en) 2024-01-09
TW202116312A (zh) 2021-05-01
JP2022541178A (ja) 2022-09-22
WO2021009695A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
MX2021012639A (es) Pirrolopirimidinas como potenciadores de cftr.
CY1122197T1 (el) ΣΚΕΥΑΣΜΑΤΑ 3-(6-(1-(2.2-ΔΙΦΘΟΡΟΒΕΝΖΟ[D][1,3]ΔΙΟΞΟΛ-5-Υλ) ΚΥΚΛΟΠΡΟΠΑΝΟΚΑΡΒΟΞΑΜΙΔΟ)-3-ΜΕΘΥΛΠΥΡΙΔΙΝ-2-Υλ)ΒΕΝΖΟΪΚΟΥ ΟΞΕΟΣ
BR112022004495A2 (pt) Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos
MX2019007135A (es) Derivados de heteroarilo biciclico como potenciadores de cftr.
PH12018500088A1 (en) Substituted tricyclics and method of use
BR112021021738A2 (pt) Derivados de amino quinazolina como inibidores de p2x3
WO2016184576A3 (en) Dry powder composition comprising long-chain rna
BR112015024073A2 (pt) Derivados de 3-acetilamino-1-(fenil-heteroaril- aminocarbonil ou fenil-heteroarilcarbonilamino) benzeno para tratamento de doenças hiperproliferativas
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
BR0316264A (pt) Medicamento para tratamento de doença pulmonar obstrutiva crÈnica
NZ709197A (en) 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
NZ602833A (en) Oral formulations of cytidine analogs and methods of use thereof
BRPI0507120A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BRPI0408047A (pt) medicamento contendo um agonista beta2 de longa duração altamente potente em combinação com outros princìpios ativos
BR112021015109A2 (pt) Conjugado de fármaco-ligante duplo e uso do mesmo
JP2017222722A5 (pt)
CL2008000399A1 (es) Sal farmaceuticamente aceptable de un derivado de propanamida; proceso para preparar dicha sal; composicion farmaceutica que comprende dicha sal; uso de dicha sal para tratar sindrome de dificultad respiratoria aguda, enfisema pulmonar, bronquitis, b
EA202092678A1 (ru) 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон
BRPI0920706B8 (pt) partículas inaláveis compreendendo tiotrópio, processos de preparação das mesmas, e composição farmacêutica
RS20080497A (en) Novel low dose pharmaceutical compositions comrising nimesulide, preparation and use thereof
BR112022000507A2 (pt) Formulações de (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida
BR112023003492A2 (pt) Composto de fórmula (i), composição farmacêutica e uso do composto
BR112021024325A2 (pt) Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
BRPI0413186A (pt) composição de fexofenadina e processo para preparação da mesma
BR112018013903A2 (pt) orvepitante para o tratamento de tosse crônica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]